The antihypertensive drug Valsartan and amlodipine tablets developed by CSPC PHARMA (01093) have been approved to conduct clinical trials.

CSPC PHARMA (01093) announced that the group's developed combination of Valsartan and Amlodipine Maleate tablets has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China. This product is the world's first approved clinical formulation composed of Valsartan and Amlodipine Maleate. Valsartan and Amlodipine are angiotensin II receptor blockers (ARB) and calcium channel blockers (CCB) respectively, both of which are well-defined antihypertensive drugs with rich experience in combination therapy in clinical practice. The approved clinical indication for this product is mild to moderate essential hypertension that cannot be effectively controlled by monotherapy. Compared to monotherapy products for hypertension, this product has clinical development value in terms of effectiveness and safety.